Lacosamide Accord (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, which stabilizes hyperexcitable neuronal membranes and diminishes the repetitive firing of neurons that underlies seizure activity.

The prescribed dose is individualized by the treating physician based on the patient’s clinical response and tolerability. Specific dosing regimens are determined by the prescriber and are not provided here.

Safety of lacosamide during pregnancy and lactation has not been established. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant.

Submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike many sodium‑channel blockers that affect fast inactivation, lacosamide selectively enhances slow inactivation, offering a distinct mechanism that may provide additional seizure control for patients not fully responsive to other agents.

Store the product at ambient temperature below 25 °C in its original packaging, protected from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged.

Lacosamide Accord is taken orally, typically as a tablet, with or without food, according to the prescribing physician’s instructions.

Serious adverse events include cardiac conduction abnormalities such as PR‑interval prolongation and atrial fibrillation, as well as severe skin reactions like Stevens‑Johnson syndrome. Patients should be monitored for these signs and seek medical attention if they occur.

Patients with known hypersensitivity to lacosamide or any of its excipients, and those with significant cardiac conduction disorders, should avoid using this medication unless specifically advised by a qualified healthcare professional.